The major element of the plan includes halting the administration of the oral polio vaccine used around the world because the attenuated serotype 2 poliovirus in the vaccine can actually cause polio.
Of the three serotypes of attenuated virus in the oral polio vaccine, the serotype 2 poliovirus accounts for roughly 40 percent of vaccine-associated paralytic polio cases and 98 percent of circulating vaccine-derived polioviruses detected in the last two years.
Additionally, the type 2 poliovirus actually interferes with and suppresses induction of immunity to serotypes 1 and 3, according to the report.
To accomplish the goal of completely eradicating polio, The WHO will have to introduce a trivalent inactivated poliovirus vaccine into routine immunization programs in all countries using oral polio vaccines to provide population immunity to type 2.
Then, the organization will be able to switch from the trivalent inactivated polio vaccine to the bivalent oral polio vaccine formula.
In doing to, WHO hopes to accomplish the global eradication of polio by 2018, according to the report.
More articles on vaccinations:
Researchers examine why parents are hesitant to vaccinate their children
Text message reminders boost second dose flu vaccines for children
Childhood vaccinations lag in 15 states
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.